What is HC Wainwright's Estimate for MDGL Q3 Earnings?

Key Points

• HC Wainwright predicts Madrigal Pharmaceuticals will report a Q3 2025 EPS of ($1.14), with a full-year estimate at ($23.47) per share and has a "Buy" rating with a target price of $500.00.
• The company recently reported quarterly earnings of ($1.90) per share, significantly beating analysts' expectations, with revenue up 1357.5% year-over-year.
• Institutional investors hold 98.50% of Madrigal's stock, indicating strong interest from large financial entities, while recent insider selling occurred from key executives.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings estimates for shares of Madrigal Pharmaceuticals in a report issued on Thursday, September 4th. HC Wainwright analyst A. Fein forecasts that the biopharmaceutical company will earn ($1.14) per share for the quarter. HC Wainwright has a "Buy" rating and a $500.00 price objective on the stock. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals' Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($6.79) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.44) EPS, Q3 2026 earnings at ($1.45) EPS, Q4 2026 earnings at ($1.48) EPS, FY2026 earnings at ($5.77) EPS, FY2027 earnings at ($4.25) EPS, FY2028 earnings at $34.48 EPS and FY2029 earnings at $69.75 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.48) by $1.58. The company had revenue of $212.80 million for the quarter, compared to analyst estimates of $158.94 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The firm's quarterly revenue was up 1357.5% on a year-over-year basis. During the same period in the prior year, the business earned ($7.10) EPS.

Other equities research analysts have also issued reports about the stock. TD Cowen raised their price objective on shares of Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the company a "buy" rating in a report on Tuesday, August 26th. UBS Group restated a "buy" rating and issued a $523.00 price objective (up from $458.00) on shares of Madrigal Pharmaceuticals in a report on Tuesday, August 12th. Canaccord Genuity Group lifted their price target on shares of Madrigal Pharmaceuticals from $428.00 to $526.00 and gave the stock a "buy" rating in a research note on Friday. JMP Securities lifted their price target on shares of Madrigal Pharmaceuticals from $483.00 to $485.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 20th. Finally, Cowen reiterated a "buy" rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 26th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $483.38.

Madrigal Pharmaceuticals Stock Down 1.6%

Shares of MDGL traded down $7.23 during midday trading on Monday, reaching $432.22. The stock had a trading volume of 190,643 shares, compared to its average volume of 374,030. Madrigal Pharmaceuticals has a 1-year low of $200.63 and a 1-year high of $457.16. The company's fifty day simple moving average is $364.11 and its two-hundred day simple moving average is $326.91. The company has a market cap of $9.60 billion, a price-to-earnings ratio of -33.64 and a beta of -1.02. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.11 and a quick ratio of 4.78.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, Director Bros. Advisors Lp Baker acquired 68,618 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The shares were acquired at an average price of $364.04 per share, with a total value of $24,979,696.72. Following the completion of the purchase, the director owned 1,859,091 shares of the company's stock, valued at approximately $676,783,487.64. This represents a 3.83% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kenneth Bate sold 10,000 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $365.20, for a total transaction of $3,652,000.00. Following the completion of the sale, the director directly owned 2,627 shares of the company's stock, valued at $959,380.40. The trade was a 79.20% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 165,683 shares of company stock valued at $61,921,142 and have sold 309,019 shares valued at $112,705,072. 21.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MDGL. China Universal Asset Management Co. Ltd. lifted its position in Madrigal Pharmaceuticals by 0.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 4,459 shares of the biopharmaceutical company's stock valued at $1,349,000 after purchasing an additional 30 shares during the last quarter. Orion Porfolio Solutions LLC boosted its holdings in shares of Madrigal Pharmaceuticals by 1.3% in the second quarter. Orion Porfolio Solutions LLC now owns 3,638 shares of the biopharmaceutical company's stock worth $1,101,000 after buying an additional 47 shares during the period. Marex Group plc acquired a new position in shares of Madrigal Pharmaceuticals in the second quarter worth about $548,000. Kestra Investment Management LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth approximately $85,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Madrigal Pharmaceuticals by 70.3% during the second quarter. Tower Research Capital LLC TRC now owns 1,851 shares of the biopharmaceutical company's stock worth $560,000 after purchasing an additional 764 shares during the period. 98.50% of the stock is owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.